NCT Number: NCT04662580
Phase: Phase 1
Trial Summary: A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Ambrx, Inc.
Acronym: ARX517
ARX517 as Monotherapy and in Combination Regimens in Subjects With Metastatic Castration-resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives